# Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

> **NCT01227655** · PHASE3 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 427 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** BIA 9-1067
- **DRUG:** Placebo
- **DRUG:** Levodopa
- **DRUG:** Carbidopa
- **DRUG:** Benserazide

## Key facts

- **NCT ID:** NCT01227655
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2015-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01227655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01227655, "Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01227655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*